GSK (NYSE: GSK) reports Share Save Plan 2022 option grants to key leaders

Rhea-AI Filing Summary

GSK plc filed a Form 6-K reporting option grants to three senior executives under the Company’s Share Save Plan 2022. James Ford (SVP and Group General Counsel, Legal and Compliance), David Redfern (President, Corporate Development), and Victoria Whyte (SVP & Company Secretary) each received options over 643 Ordinary Shares of 31¼ pence at an option price of £14.19 per share.

The grants were made on 2025-11-28 and relate to GSK’s Ordinary Shares with ISIN GB00BN7SWP63, with the transactions conducted on the London Stock Exchange (XLON). These awards form part of GSK’s regular share-based compensation for senior management and do not change the company’s stated business strategy as a global biopharma company.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The grant of options over Ordinary Shares pursuant to the Company's Share Save Plan 2022
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.19	643
d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2025-11-28
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The grant of options over Ordinary Shares pursuant to the Company's Share Save Plan 2022
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.19	643
d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2025-11-28
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The grant of options over Ordinary Shares pursuant to the Company's Share Save Plan 2022
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.19	643
d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2025-11-28
f)	Place of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: December 01, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What insider transactions did GSK (GSK) report in this Form 6-K?

GSK reported the grant of options over its Ordinary Shares to three senior executives under the Company’s Share Save Plan 2022, with each grant relating to 643 shares at an exercise price of £14.19 per share on 2025-11-28.

Which GSK (GSK) executives received share options and in what amount?

Options were granted to James Ford (SVP and Group General Counsel, Legal and Compliance), David Redfern (President, Corporate Development), and Victoria Whyte (SVP & Company Secretary). Each received options over 643 Ordinary Shares at £14.19 per share.

What share class is involved in the GSK (GSK) option grants reported?

The option grants relate to GSK’s Ordinary Shares of 31¼ pence each, with ISIN GB00BN7SWP63, traded on the London Stock Exchange (XLON).

On what date were the GSK (GSK) share options granted and where were they transacted?

The options were granted on 2025-11-28, and the transactions are recorded as having taken place on the London Stock Exchange (XLON).

Under which plan were the GSK (GSK) options granted to executives?

The options were granted pursuant to GSK’s Share Save Plan 2022, which provides share option awards over GSK Ordinary Shares to eligible participants.

Does this GSK (GSK) filing indicate any change to the company’s core business?

No. The filing describes routine share option grants to senior executives. GSK reiterates that it is a global biopharma company focused on uniting science, technology, and talent to get ahead of disease.